Nautilus Biotechnology, Inc.
NAUT- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001808805
No open-market purchases or sales by Nautilus Biotechnology, Inc. insiders were filed in the last 90 days; 93 institutions reported holding it in 13F filings for Q2 2026, worth $93.7M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Nautilus Biotechnology, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 75 | 1 | 76 | +2 |
| Shares | 45.1M | 1.36M | 63.4M | +19.7M (+45.0%) |
| Value | $142.5M | $4.28M | $189.6M | +$51.5M (+37.2%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Nautilus Biotechnology, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AH Capital Management, L.L.C. | 17,653,917 | $52.8M | 3.25% |
| Virtu Financial LLC | 26,337 | $79.0K | 0.01% |
| Susquehanna International Group, LLP | 21,710 | $64.9K | 0.00% |
| Millennium Management LLC | 11,176 | $33.4K | 0.00% |
| Axxcess Wealth Management, LLC | 10,000 | $29.9K | 0.00% |
| Presidio Capital Management, LLC | 10,000 | $29.9K | 0.02% |
| Simplex Trading, LLC | 836 | $2.00K | 0.00% |
| GAMMA Investing LLC | 105 | $292 | 0.00% |
Sold out (6)
Institutions that held Nautilus Biotechnology, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Botty Investors LLC | 1,449,551 | $4.58M |
| CI Private Wealth, LLC | 45,350 | $143.3K |
| Bridgeway Capital Management, LLC | 38,800 | $122.6K |
| Kestra Private Wealth Services, LLC | 11,897 | $37.6K |
| PDS Planning, Inc | 10,455 | $33.0K |
| Financial Synergies Wealth Advisors, Inc. | 291 | $920 |
Not filed for Q4 2023 yet (1)
Institutions that held Nautilus Biotechnology, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $4.28M |